Albany Molecular Research Long Term Debt

Albany Molecular Research (AMRI) currently reports a long-term debt of $200M as of June 2017. That compares with $370M in the prior-year period — down 47.3% year over year. Use the charts on this page to explore Albany Molecular Research's long-term debt history and peer comparisons.

Albany Molecular Research's long-term debt decreased from $370M to $200M — a 47.3% year-over-year decrease (period ending June 2017). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Albany Molecular Research reported $200M in long-term debt as of June 2017. That compares with $370M in the prior-year period — down 47.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $200M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Albany Molecular Research, and consider following AMRI for alerts when major investors trade the stock.